|
| 产品描述 |
| JNJ-26483327, also known as BGB102, is an orally bioavailable, small-molecule, multitargeted reversible tyrosine kinase inhibitor with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor JNJ-26483327 binds to and inhibits several members of the epidermal growth factor receptor (EGFR) family, including EGFR, HER2 and HER4; Src family kinases (Lyn, Yes, Fyn, Lck and Src); and vascular endothelial growth factor receptor type 3 (VEGFR3). |
| 化学结构 |
 |
| 化学名称 |
| 35-bromo-17-methoxy-5-methyl-11-oxa-2,5-diaza-1(4,6)-quinazolina-3(1,2)-benzenacycloundecaphan |
| SMILES Code |
| CN1CCCCCOC(C(OC)=C2)=CC3=C2N=CN=C3NC4=CC(Br)=CC=C4C1 |
| 基本信息 |
产品编号:XM246
产品名称:JNJ-26483327
别名:JNJ26483327; JNJ 26483327; JNJ-26483327; BGB102; BGB-102; BGB 102.
CAS#:807640-87-5 (free base); 1021686-80-5 (2HBr salt).
分子式:C22H25BrN4O2
精确分子量:456.11609
分子量:457.3635
|
| 物化性质 |
外观: 白色或类白色固体粉末
纯度: >98%
运输信息: 非危险化学品，适于常温或冰袋运输。
储存条件: 低温，干燥，避光。
溶解性: 溶于DMSO, 不溶于水
储存期限:3年 -20℃固体储存
2 年 -80℃ 溶液储存 |
该产品只供科研使用，不能给病人提供。
|
|
|
